Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adrenoleukodystrophy Therapy
Reports from M. Deon and colleagues advance knowledge in adrenoleukodystrophy therapy
April 13th, 2008
Fresh data on adrenoleukodystrophy are presented in the report 'Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy.' "X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disease biochemically characterized by the accumulation of very long chain fatty acids (VLCFA), particularly hexacosanoic (C26:0) and tetracosanoic acids (C24:0) in different tissues and in biological fluids and clinically characterized by central and peripheral demyelination and adrenal insufficiency. A considerable number of heterozygotes (HTZ) for X-ALD develop neurological symptoms like spinal cord involvement resembling milder forms of adrenomyeloneuropathy," scientists in Porto Alegre,...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
|
Advertisement |
|
|
|
